# Gene Therapy Market > 基因治疗市场研究报告按治疗领域（肿瘤、遗传性疾病、传染病、心血管疾病、神经系统疾病）、按技术（病毒载体、CRISPR、基因编辑、RNA 治疗、非病毒方法）、按应用（研究、临床、商业）、按给药途径（静脉内、肌内、皮内、鞘内、口服）和区域（北美、欧洲、南美洲、亚太地区、中东和非洲）- 2035 年预测 - **Forecast Period:** 2025 - 2035 - **CAGR:** 19.04% - **2024:** $ 6.12 Billion - **2025:** $ 7.28 Billion - **2035:** $ 41.63 Billion - **Key Players:** Companies such as Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Sangamo Therapeutics (US), CRISPR Therapeutics (CH), AstraZeneca (GB), Roche (CH) are some of the major participants in the global market. **Report ID:** MRFR/Pharma/6927-CR · **Pages:** 167 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 21, 2026 **URL:** https://www.marketresearchfuture.com/reports/gene-therapy-market-8399 --- ## Market Summary ## **Gene Therapy Market Overview** The Gene Therapy Market was valued at USD 6.11 Billion in 2024. The Gene Therapy Market industry is projected to grow from USD 7.24 Billion in 2025 to USD 46.91 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 19.04% during the forecast period (2025-2035). The growing incidences and prevalence of cancer and rare disorders and increasing approval for gene therapy products and favourable government support for gene therapy are driving the growth of the Gene Therapy Market. As per the Analyst at MRFR, the growing incidences of cancer and rare disorders are significantly fueling the Gene Therapy Market as the demand for innovative treatments escalates. As cancer rates rise and the prevalence of rare genetic disorders increases, traditional therapeutic options often fall short, creating a pressing need for advanced solutions. Gene therapy, with its potential to address the underlying genetic causes of these conditions, offers a promising alternative by targeting and modifying the specific genes involved.  For instance, according to the International Agency for Research on Cancer, there were cancer cases of nearly 9,826,539 in Asia, 4,471,422 in Europe, 2,673 174 in Northern America, 1,551,060 in Latin America and the Caribbean, 1,185,216 in Africa, and 269 088 in Oceania cancer cases of both genders in 2022. Furthermore, India also reported increasing incidences of cancer, which is contributing to the growth of the global gene therapy market. ** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review** ## **Gene Therapy Market****Opportunity** **GROWING INVESTMENT IN THE FIELD OF GENE THERAPY** The increasing investment in gene therapy is one of the major opportunities across the globe. The growing investment leads to an increase in the availability of technological advancements, including CRISPR-Cas9. Also, the investment assists in developing gene therapy with a focus on broad therapeutic areas. Furthermore, rising funding also assists in expanding the market, which fosters collaboration, competition, innovation, and investment. For instance, - June 2024: Beacon Therapeutics (US) has secured $170 million in Series B funding to propel its work on ophthalmic gene therapies. This round was led by Forbion, with participation from existing investors Syncona and Oxford Science Enterprises, along with new contributors TCGX and Advent Life Sciences. The funds are earmarked to advance the clinical development of their lead asset, AGTC-501, which is targeting X-Linked Retinitis Pigmentosa (XLRP), and to generate data for their Dry Age-related Macular Degeneration (dAMD) program. - February 2024: Vivet Therapeutics received USD 5.35 million in funding from the French government through the France Health Innovation Plan 2030, which will significantly boost the development of a gene therapy aimed at treating this rare and debilitating condition. CTX is a rare genetic disorder that impairs the body’s ability to metabolize cholesterol, leading to the accumulation of fatty deposits in various tissues, including the brain. This results in a range of serious symptoms, from chronic diarrhea in infancy to progressive neurological issues like dementia and seizures in adulthood. Currently, treatment options are limited to managing symptoms and slowing the progression of the disease. - January 2024: Novartis AG (Switzerland) signed a deal with Voyager Therapeutics (US) in order to pay USD 100 million upfront as a part of a licensing deal to develop gene therapy candidates for genetic disorders. - June 2023: Laurus Labs (India) invested USD 9.59 million for gene therapy firm ImmunoACT (India). ImmunoACT will be able to accelerate the scale-up of its lead candidate, HCAR-19, by expanding its multi-location cGMP facilities with the new funding. The data show a global increase in investment and collaboration in the gene therapy sector. Companies such as Beacon Therapeutics, Vivet Therapeutics, Novartis AG, and Laurus Labs are strategically collaborating and investing in R&D and manufacturing facilities to accelerate the commercialization and scaling-up of innovative gene therapies. ## **Gene Therapy Market****Segment Insights** ### **Gene Therapy****System by Vector Type Insights** Based on Vector Type, this segment includes Viral Vector (Lentiviral Vectors (LVVs), Retrovirus Vectors, Adenoviral Vectors (AdVs) and Adeno-associated Viral Vectors (AAVs)) and Non-Viral Vector (Physical Vector, Chemical Vector). The Viral Vector segment dominated the global market in 2024, while the Non-Viral Vector is projected to be the fastest–growing segment during the forecast period. Among viral vectors, adeno-associated viruses (AAVs) and lentiviral vectors (LVVs) are widely used for their safety profiles and long-term gene expression.  Non-viral vectors, including physical methods (like electroporation) and chemical carriers (like lipid nanoparticles), offer lower immunogenicity and easier large-scale manufacturing. The success of lipid nanoparticle-based mRNA vaccines during the COVID-19 pandemic has accelerated interest and innovation in non-viral delivery systems. Additionally, advancements in nanotechnology and material sciences are enhancing the efficiency and targeting capability of non-viral vectors, making them an attractive option for next-generation gene therapies and expanding their potential across various therapeutic areas. **FIGURE 2: GENE THERAPY MARKET SHARE BY VECTOR TYPE 2024 AND 2035 (USD BILLION)** Source: Secondary Research, Primary Research, MRFR Database and Analyst Review ### **Gene Therapy****System****by Gene Type****Insights** Based on Gene Type, this segment includes Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others. The Antigen segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. These therapies have shown remarkable clinical success and have received regulatory approvals, boosting market confidence. Additionally, antigen-based approaches are expanding into other areas such as infectious diseases and autoimmune disorders, supported by advancements in gene delivery technologies and personalized medicine.  The segment benefits from a robust pipeline, significant investment, and favorable regulatory designations like orphan drug and breakthrough therapy status, which accelerate development and commercialization. Overall, the antigen segment's ability to deliver targeted, effective, and personalized treatments positions it as a key driver of innovation and growth in the gene therapy landscape. ### **Gene Therapy****System****by Application****Insights** Based on Application, this segment includes Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, and Others. The Oncological Disorders segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. This is primarily due to the rising global cancer burden and the increasing adoption of gene therapies like [CAR-T cell therapy](../../../reports/car-t-cell-therapy-market-8102) and oncolytic viruses, which offer targeted and effective treatment options.  Advances in personalized medicine and immune-based gene therapies have shown significant success in treating hematologic and solid tumors, driving demand. Additionally, strong clinical pipelines, regulatory approvals, and substantial investments in cancer gene therapy research are fueling growth. The high unmet need for more effective cancer treatments and the ability of gene therapy to address previously untreatable cancers further strengthen this segment’s market position. ### **Gene Therapy****System****by Delivery Method****Insights** Based on the Delivery Method, this segment includes In Vivo Gene Therapy and Ex Vivo Gene Therapy. The In Vivo Gene Therapy segment dominated the global market in 2024, while it is projected to be the fastest–growing segment during the forecast period. This method involves directly delivering genetic material into a patient’s body, allowing for simpler, less invasive procedures compared to Ex Vivo approaches. In Vivo therapies are particularly effective for treating genetic and rare diseases, especially those affecting the liver, muscles, and central nervous system.  The rise of adeno-associated viral ([AAV](../../../de/reports/adeno-associated-virus-aav-vector-based-gene-therapy-market-29672)) vectors and lipid nanoparticles has improved the safety and precision of in vivo delivery. Additionally, reduced complexity, lower treatment costs, and faster clinical translation are driving increased adoption. Growing research investments and successful clinical trials continue to accelerate development in this segment. ### **Gene Therapy****System Regional Insights** Based on the Region, the global Gene Therapy is segmented into North America, Europe, Asia-Pacific and Rest of the World. Major demand factors driving the North America market are the growing incidences and prevalence of cancer and rare disorders and increasing approval for gene therapy products and favourable government support for gene therapy. Additionally, the availability of reimbursements and insurance coverage is making gene therapies more accessible to patients. Increased healthcare expenditure and investment in research and development are further fueling market expansion.  Supportive regulatory frameworks and incentives are streamlining the approval process, while strategic partnerships and collaborations are accelerating innovation. The pipeline of gene therapy drugs includes a wide range of treatments for various genetic and acquired diseases, such as rare genetic disorders, cancer, and autoimmune diseases. The potential of these drugs to provide targeted and personalized treatments for patients with complex medical conditions has generated significant interest from biopharmaceutical companies, investors, and healthcare providers. The competitive landscape features established players who have adopted strategies such as acquisition, agreement, strategic alliance, collaboration, clinical trial, expansion, joint venture, new product development, and product approval to expand their product portfolio. **FIGURE 3: GENE THERAPY MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, Australia, Middle East & Africa, South America and others. **Global Gene Therapy Key Market Players & Competitive Insights** Many global, regional, and local vendors characterize the Gene Therapy Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major competitors in the market are Bristol-Myers Squibb Company, Lonza, UniQure N.V., Bluebird Bio, Inc., Orchard Therapeutics Plc, GenSight Biologics, Novartis AG, Amgen Inc., Sarepta Therapeutics Inc., Spark Therapeutics, Inc., are among others. The Gene Therapy Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness. **Key Companies in the****Gene Therapy Market****include** - Bristol-Myers Squibb Company - [Lonza](https://www.lonza.com/specialized-modalities/cell-and-gene) - UniQure N.V. - Bluebird Bio, Inc. - Orchard Therapeutics Plc - GenSight Biologics - Novartis AG - Amgen Inc. - Sarepta Therapeutics Inc. - Spark Therapeutics, Inc., **Gene Therapy Market****Industry Developments** **January 2024:** Novartis AG has entered into a strategic partnership with Voyager Therapeutics, Inc., which includes an exclusive license for Voyager's TRACER capsids and related intellectual property. This collaboration will focus on developing a preclinical gene therapy candidate for Huntington's Disease (HD). **October 2023:** SpliceBio, a genetic medicines company specializing in Protein Splicing to advance gene therapies, has announced an exclusive collaboration and licensing agreement with Spark Therapeutics. This partnership will leverage SpliceBio's proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. **December 2023:**Bluebird bio, Inc. (US) received an approval from US Food Drug and Administration for Lyfgenia representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. **September 2021:** GenSight Biologics announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has designated its gene therapy LUMEVOQ as a Promising Innovative Medicine (PIM) for the treatment of vision loss caused by Leber Hereditary Optic Neuropathy (LHON), which is caused by a confirmed G11778A mutation in the ND4 mitochondrial gene. ## **Gene Therapy Market****Segmentation** ### **Gene Therapy by Vector Type Outlook** - Viral Vector - Lentiviral Vectors (LVVs) - Retrovirus Vectors - Adenoviral Vectors (AdVs) - Adeno-associated Viral Vectors (AAVs) - Non-Viral Vector - Physical Vector - Chemical Vector ### **Gene Therapy by Gene Type Outlook** - Antigen - Cytokine - Tumor Suppressor - Suicide - Deficiency - Growth Factors - Receptors - Others ### **Gene Therapy by Application Outlook** - Oncological Disorders - Rare Diseases - Cardiovascular Diseases - Neurological Disorders - Infectious Diseas - Others ### **Gene Therapy by Delivery Method Outlook** - In Vivo Gene Therapy - Ex Vivo Gene Therapy ### **Gene Therapy****Regional Outlook** - North America - US - Canada - Europe - Germany - France - UK - Italy - Spain - Rest of Europe - Asia-Pacific - China - India - Japan - South Korea - Australia - Rest of Asia-Pacific - Rest of the world - Middle East & Africa - South America ## Market Drivers ### Increasing Funding and Investment 基因治疗行业正在经历来自公共和私营部门的资金和投资的激增。政府和风险资本家正在认识到基因疗法彻底改变治疗模式的潜力，从而增加对研究计划的财政支持。近年来，基因治疗项目的资金不断增加，已分配数十亿美元用于支持临床试验和产品开发。   这种资本的涌入可能会加快市场创新的步伐，促进新疗法的开发，以满足未满足的医疗需求。此外，生物技术公司和学术机构之间的合作关系变得越来越普遍，进一步推动了推进基因治疗研究和商业化的合作努力。   - 根据 PubMed 研究出版物，近年来基因治疗研究显着增加，反映出全球强劲的科学投资和创新。越来越多的临床调查和研究合作表明，对开发先进基因药物和加速商业化机会的资金支持不断扩大。 ### Growing Demand for Targeted Therapies 向个性化和靶向治疗的转变是基因治疗行业的显着驱动力。患者和医疗保健提供者越来越多地寻求基因疗法可以提供的针对个体遗传特征的治疗方法。这一趋势得到了基因组学和生物技术进步的支持，使得能够开发针对特定基因突变的疗法。   截至 2025 年，靶向治疗市场预计将大幅增长，反映出更广泛的精准医疗趋势。该市场处于有利地位，可以充分利用这一需求，因为它提供了符合个性化医疗保健原则的创新解决方案。因此，对靶向治疗的重视可能会推动基因治疗领域的进一步投资和研究。   - IHME 数据显示，由于复杂的慢性病，​​全球疾病负担持续增加，这就产生了对精准治疗方法的需求。对特定疾病干预措施的不断增长的需求支持了靶向治疗的采用，包括旨在提高治疗效果和患者预后的基于基因的解决方案。 ### Rising Prevalence of Genetic Disorders 遗传性疾病发病率的增加是基因治疗行业的主要驱动力。血友病、肌营养不良症和囊性纤维化等疾病变得越来越普遍，需要创新的治疗方案。根据最近的估计，大约每 1,500 人中就有 1 人患有血友病，这突出表明迫切需要有效的治疗方法。   不断增长的患者群体可能会推动对基因疗法的需求，因为传统疗法往往疗效不佳。因此，随着医疗保健提供者寻求先进的解决方案来解决这些复杂的遗传状况，市场将显着扩大。此外，患者和医疗保健专业人员对基因疗法提供长期解决方案的潜力的认识不断提高，预计将进一步刺激市场增长。 ### Technological Advancements in Gene Editing 基因编辑技术的技术创新，例如 CRISPR-Cas9 和 TALEN，正在改变基因治疗行业。这些进步使得能够对遗传物质进行精确修饰，从而提高基因疗法的功效和安全性。高精度靶向特定基因的能力为治疗以前无法治疗的疾病开辟了新途径。   截至2025年，基因编辑技术市场预计将达到数十亿美元，显示出强劲的增长潜力。技术能力的激增可能会吸引大量投资，促进市场的进一步研究和开发。因此，这些尖端技术的整合预计将加速新型基因疗法的批准和商业化，从而扩大市场格局。 ### Regulatory Support and Streamlined Approval Processes 监管机构通过简化新疗法的审批流程越来越多地为基因治疗行业提供支持。旨在加快基因疗法审查的举措正在实施，这可能会大大缩短创新疗法进入市场所需的时间。   例如，快速通道指定和优先审查途径的引入正在鼓励公司投资基因疗法开发。这种监管环境可能会为市场创造更有利的环境，因为它提高了产品成功推出的可能性。因此，支持性法规和不断增长的基因疗法管道的结合预计将有助于市场的整体扩张。 ## Future Outlook The Gene Therapy Market size is projected to reach USD 41.63 Billion by 2035, growing at a CAGR of 19.04%, driven by advancements in gene therapy technology, increasing investments, and rising prevalence of genetic disorders. **New opportunities:** - Development of personalized gene therapies targeting rare diseases. - - Expansion of partnerships with biotech firms for innovative delivery systems. - Investment in AI-driven platforms for gene therapy research and development. By 2035, the Gene Therapy Market is expected to be a pivotal sector in healthcare innovation. ## Segment Insights ### 按载体类型：病毒载体（最大）与非病毒载体（增长最快） 在基因治疗市场中，载体类型细分市场主要由病毒载体主导，由于其效率和有效传递遗传物质的能力，病毒载体已以 65% 的份额奠定了坚实的基础。非病毒载体虽然目前不太占主导地位，但由于具有安全性和可扩展性等优势，正在获得关注，推动细胞和市场动态的逐渐转变。随着这两种类型都取得了更多的进步，它们之间的竞争也在加剧，使得形势变得越来越复杂。 Bluebird Bio 通过创新产品的进步，加强了基于病毒载体的基因治疗的开发。该公司的 Lyfgenia 基因疗法获得 FDA 批准用于治疗镰状细胞病，这是慢病毒载体技术的一个重要里程碑，并展示了病毒载体治疗应用的持续进展。 ### 按基因类型：抗原（最大）与细胞因子（增长最快） 在基因治疗市场中，基因类型可分为几个部分，即抗原、细胞因子、肿瘤抑制因子、自杀基因、缺陷基因、生长因子、受体等。其中，Antigen 成为最大的细分市场，占整体市场份额的 28%。细胞因子迅速出现，表现出最快的增长。其他基因类型也显示出潜力，但抗原和细胞因子由于其巨大的治疗意义和临床进展而主导了细胞和基因治疗市场的讨论。基因类型市场的增长趋势反映了生物技术进步和研发投资增加所驱动的动态格局。遗传性疾病发病率的上升推动了对有效疗法的需求，特别是利用抗原和细胞因子的疗法。基因编辑技术的创新和制药公司之间加强的合作是使这些细分市场在竞争激烈的市场中蓬勃发展的关键驱动力。 百时美施贵宝继续通过其肿瘤学产品线推进以抗原为中心的免疫治疗创新。该公司对基于免疫疗法的投资支持靶向治疗方法的开发，加强基于抗原的策略在下一代遗传和细胞医学应用中的作用。 ### 按应用分类：肿瘤疾病（最大）与罕见疾病（增长最快） 在基因治疗市场的应用领域中，肿瘤疾病因其复杂的治疗需求和研究投资而占据最大的市场份额，达到42%。随着生物制药公司集中精力提供针对各种癌症的创新疗法，这种情况影响了一半以上的基因治疗开发。另一方面，罕见疾病虽然市场份额较小，但正在出现前所未有的增长。它们的专业化和孤儿药的出现引起了人们的广泛关注，从而导致了快速进步和靶向治疗。 CRISPR Therapeutics 通过先进的临床项目扩大了以肿瘤学为中心的基因治疗创新。该公司的 Casgevy 疗法获得了针对遗传性血液疾病的监管批准，展示了基因编辑技术的潜力，并支持遗传药物在复杂疾病领域的更广泛应用。 ### 按递送方式：体内基因治疗（最大）与体外基因治疗（增长最快） 在基因治疗市场中，体内基因治疗领域占据最大份额，达到 55%，占整个市场的很大一部分。该细分市场受益于其简单的应用过程，其中治疗剂直接输送到患者体内。它被广泛用于治疗各种遗传性疾病和疾病，使其成为医疗保健提供者和患者的首选。与此同时，体外基因疗法（细胞在体外进行修饰然后重新引入）正在迅速获得关注，并被认为是增长最快的领域。这种方法允许采用更受控的基因传递方法，迎合特定市场，但随着定制疗法变得更加普遍，市场不断扩大。 阿斯利康通过专注于下一代疗法的战略投资和合作加强了其基因医学产品线。该公司继续探索先进的递送技术以改进靶向治疗方法，支持体内基因治疗应用的扩展。 ## Regional Market Share Analysis ### 北美：领先的创新和投资 北美在全球基因治疗市场规模中占据最大份额，到 2024 年将达到 28 亿美元。该地区受益于强劲的研发投资、强大的监管框架以及对创新疗法的高需求。 - 根据疾病预防控制中心的数据，美国有数百万人受到慢性和遗传相关健康状况的影响，这增加了对先进疗法的需求。强大的医疗基础设施和不断提高的疾病意识继续支持北美地区对创新基因治疗解决方案的采用和投资。 竞争格局的特点是生物技术公司和学术机构之间的重大合作，促进创新。加拿大也发挥着至关重要的作用，增加了对基因治疗研发的投资，进一步巩固了北美在该领域的领导者地位。 - 百时美施贵宝通过对细胞和基因治疗研究的大量投资，继续扩大北美的先进治疗能力。该公司的创新管道和监管成就凸显了该地区开发和商业化下一代基因药物的强大生态系统。 ### 欧洲：监管进步和增长 欧洲是基因治疗的第二大市场，约占全球市场份额的30%。在欧洲药品管理局 (EMA) 基因治疗指南等监管框架进步的推动下，该地区正在经历显着增长。这些法规旨在简化审批流程，鼓励该行业的创新和投资。 - 据 EMA 称，欧洲已经为包括基因疗法在内的先进治疗药物产品（ATMP）建立了强有力的监管框架。该机构支持多种创新疗法的批准，使患者能够更快地获得药物，并鼓励对欧洲不断发展的基因治疗生态系统进行制药投资。 欧洲的主要国家包括德国、法国和英国，这些国家是诺华 (Novartis) 和阿斯利康 (AstraZeneca) 等几家主要企业的所在地。随着制药公司和研究机构之间的合作不断增加，竞争格局正在不断变化。完善的医疗基础设施进一步支持了基因治疗的发展，使欧洲成为全球基因市场的重要参与者。 ### 亚太地区：快速增长和投资 亚太地区正在迅速崛起，成为市场的重要参与者，约占全球市场份额的 20%。该地区的发展动力来自于生物技术投资的增加、患者人数的增加以及医疗保健支出的增加。中国和日本等国家处于领先地位，政府出台了旨在促进基因疗法创新的支持性政策。 中国尤其值得关注，临床试验激增，越来越多的生物技术公司进入基因市场。日本先进的医疗保健系统和监管支持也促进了该地区的增长。竞争格局的特点是本地和国际参与者，包括 CRISPR Therapeutics 和 Sangamo Therapeutics，它们正在积极寻求合作伙伴关系以增强其市场占有率。 ### 中东和非洲：充满挑战的新兴市场 中东和非洲（MEA）地区仍处于市场的萌芽阶段，约占全球市场份额的5%。增长受到医疗基础设施有限、监管障碍以及研发资金缺乏等挑战的阻碍。 然而，由于公共和私营部门的意识和投资不断提高，人们对基因疗法的兴趣日益浓厚。南非和阿联酋等国家开始投资生物技术，采取旨在改善医疗保健服务和创新的举措。竞争格局仍在发展，一些本地企业和国际公司在该地区探索机会。随着医疗保健基础设施的改善，中东和非洲地区的市场有望逐步增长。 ## Competitive Benchmarking 基因治疗市场目前的特点是动态竞争格局，受到技术快速进步和对个性化医疗日益关注的推动。诺华（瑞士）、吉利德科学（美国）和蓝鸟生物（美国）等主要参与者处于前沿，利用其创新能力来增强遗传性疾病的治疗选择。诺华（瑞士）通过战略合作伙伴关系和强大的基因治疗产品线将自己定位为领导者，而吉利德科学（美国）则强调其对研发的承诺，特别是在罕见疾病领域。 另一方面，Bluebird Bio（美国）专注于通过合作扩大其治疗产品，从而塑造一个越来越依赖创新和战略联盟的竞争环境。   在商业策略方面，企业越来越多地进行本地化制造和优化供应链，以提高效率并降低成本。该市场似乎适度分散，既有老牌企业，也有新兴生物技术公司。这种结构允许多种治疗选择，尽管罗氏（瑞士）和百时美施贵宝（美国）等大公司的集体影响力很大，因为它们继续大力投资于研发以保持竞争优势。   2025年8月，吉利德科学公司（美国）宣布与一家领先的学术机构开展突破性合作，开发下一代基因编辑技术。此次合作预计将加速创新疗法的开发，有可能改变遗传性疾病的治疗模式。此次合作的战略重要性在于吉利德利用学术专业知识的能力，这可能会增强其研究能力并加快新疗法进入基因市场的道路。   2025 年 9 月，Bluebird Bio（美国）在临床试验成功后推出了一种新的基因治疗产品，旨在治疗罕见的遗传疾病。此次推出不仅使蓝鸟的产品组合更加多元化，还强调了其致力于解决未满足的医疗需求的承诺。此举具有深远的战略意义，因为它使蓝鸟成为基因市场的关键参与者，有可能增加其市场份额并增强其创新声誉。   2025 年 10 月，诺华 (CH) 通过在瑞士投资一座新工厂扩大了其基因治疗制造能力。这项战略投资可能会提高生产效率和可扩展性，使诺华能够满足全球对其疗法不断增长的需求。此次扩张的影响是巨大的，因为它可能会巩固诺华在基因治疗领域的领导者地位，使其能够迅速响应市场需求和监管变化。   截至 2025 年 10 月，市场正在见证强调数字化、可持续性以及人工智能在研发过程中集成的趋势。战略联盟日益塑造竞争格局，促进关键参与者之间的创新和协作。展望未来，竞争差异化似乎将从传统的基于价格的竞争演变为注重技术进步、创新疗法和可靠的供应链，从而改善患者的治疗效果并推动市场增长。 ## Recent News & Developments **January 2024:** Novartis AG has entered into a strategic partnership with Voyager Therapeutics, Inc., which includes an exclusive license for Voyager's TRACER capsids and related intellectual property. This collaboration will focus on developing a preclinical gene therapy candidate for Huntington's Disease (HD). **October 2023:** SpliceBio, a genetic medicines company specializing in Protein Splicing to advance gene therapies, has announced an exclusive collaboration and licensing agreement with Spark Therapeutics. This partnership will leverage SpliceBio's proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. **December 2023:**Bluebird bio, Inc. (US) received an approval from US Food Drug and Administration for Lyfgenia representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. **September 2021:** GenSight Biologics announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has designated its gene therapy LUMEVOQ as a Promising Innovative Medicine (PIM) for the treatment of vision loss caused by Leber Hereditary Optic Neuropathy (LHON), which is caused by a confirmed G11778A mutation in the ND4 mitochondrial gene. ## Report Scope | MARKET SIZE 2024 | 6.12(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 7.285(USD Billion) | | MARKET SIZE 2035 | 41.63(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Sangamo Therapeutics (US), CRISPR Therapeutics (CH), AstraZeneca (GB), Roche (CH) | | Segments Covered | Vector Type, Gene Type, Applications, Delivery Method | | Key Market Opportunities | Advancements in personalized medicine are driving growth in the Gene Therapy Market. | | Key Market Dynamics | Rising regulatory approvals and technological advancements are driving innovation and competition in the gene therapy market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Gene Therapy Market as of 2024?** A: The Gene Therapy Market was valued at 6.12 USD Billion in 2024. **Q: What is the projected market size for the Gene Therapy Market by 2035?** A: The market is projected to reach 41.63 USD Billion by 2035. **Q: What is the expected CAGR for the Gene Therapy Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Gene Therapy Market during 2025 - 2035 is 19.04%. **Q: Which companies are considered key players in the Gene Therapy Market?** A: Key players include Novartis, Gilead Sciences, Spark Therapeutics, and Bluebird Bio, among others. **Q: What are the main segments of the Gene Therapy Market based on vector type?** A: The main segments based on vector type are Viral Vector, valued at 25.0 USD Billion, and Non-Viral Vector, valued at 16.63 USD Billion. **Q: How do the different gene types perform in the Gene Therapy Market?** A: In 2024, Antigen and Tumor Suppressor gene types were valued at 5.5 USD Billion and 6.2 USD Billion, respectively. **Q: What applications dominate the Gene Therapy Market?** A: Oncological Disorders and Rare Diseases are leading applications, valued at 5.92 USD Billion and 8.12 USD Billion in 2024. **Q: What delivery methods are utilized in the Gene Therapy Market?** A: The market segments include In Vivo Gene Therapy, projected to reach 25.09 USD Billion, and Ex Vivo Gene Therapy, expected to reach 16.54 USD Billion. **Q: What is the potential growth of the Gene Therapy Market in the coming years?** A: The Gene Therapy Market appears poised for substantial growth, with projections indicating a significant increase by 2035. **Q: How does the Gene Therapy Market compare to other biopharmaceutical sectors?** A: The Gene Therapy Market, with its projected growth, suggests a robust position compared to other biopharmaceutical sectors, particularly in innovative treatments. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gene-therapy-market-8399*